Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study

OBJECTIVES: While immune checkpoint inhibitors (ICIs) continue to transform the neoadjuvant treatment, its association with postoperative acute hypoxemic respiratory failure (AHRF) remains unexplored. This study aims to assess the association between neoadjuvant immunochemotherapy (nICT) and postoperative AHRF risk following thoracic tumour surgeries and identify the risk subgroups. METHODS: = 160) before thoracic tumour surgeries from December 2017 to June 2023. Data were analysed by using the propensity score matching (PSM) and multivariable logistic regressions. Subgroup and sensitivity analyses were performed to test the stability of the conclusions. RESULTS: = 0.002). The inverse probability-weighting model (IPTW) confirmed elevated AHRF risk associated with nICT compared to nCT (OR = 2.41, 95% CI: 1.2-4.82). In patients with non-small cell lung cancer (NSCLC), the binary logistic regression analysis showed that the history of nICT was significantly associated with postoperative AHRF (OR = 4.12, 95% CI: 1.15-14.8) in patients with NSCLC. Subgroup analyses revealed elevated AHRF risks with nICT versus nCT in patients with time interval between neoadjuvant therapy and surgery within 42 days (OR = 6.68, 95% CI: 1.24-35.98), those with squamous cell carcinoma (SCC) (OR = 3.64, 95% CI: 1.41-9.44), and those who did not achieve pathologic complete response (non-pCR) (OR = 2.82, 95% CI: 1.14-6.98). CONCLUSIONS: nICT was associated with increased postoperative AHRF risk in thoracic surgical patients, necessitating rigorous perioperative monitoring.